Boyle D M, Barber J M, McIlmoyle E L, Salathia K S, Evans A E, Cran G, Elwood J H, Shanks R G
Br Heart J. 1983 Mar;49(3):229-33. doi: 10.1136/hrt.49.3.229.
All patients with a presumptive diagnosis of myocardial infarction, who were seen within six hours of the onset of symptoms and had no reason for exclusion, were considered for entry into a trial to compare the effects of metoprolol and placebo on creatine kinase MB isoenzyme release. The trial was randomised and double blind. The median time from onset of symptoms to receiving trial drug was just under two hours. Two hundred and four patients (of whom 120 had myocardial infarction) received metoprolol and 187 (of whom 105 had myocardial infarction) received placebo. Infarct size was estimated semiquantitatively using cumulative release of the cardiospecific isoenzyme, creatine kinase MB. Mean creatine kinase MB isoenzyme was less in patients who received metoprolol, but the reduction did not achieve statistical significance. Clinical problems related to early intravenous metoprolol were uncommon.
所有初步诊断为心肌梗死且在症状发作后6小时内就诊且无排除理由的患者，均被考虑纳入一项试验，以比较美托洛尔和安慰剂对肌酸激酶MB同工酶释放的影响。该试验采用随机双盲设计。从症状发作到接受试验药物的中位时间略低于两小时。204例患者（其中120例患有心肌梗死）接受了美托洛尔治疗，187例患者（其中105例患有心肌梗死）接受了安慰剂治疗。使用心脏特异性同工酶肌酸激酶MB的累积释放量对梗死面积进行半定量估计。接受美托洛尔治疗的患者肌酸激酶MB同工酶的平均值较低，但降低幅度未达到统计学显著性。与早期静脉注射美托洛尔相关的临床问题并不常见。
